Safety of Cefpodoxime with Apixaban

Drug Interaction Assessment

Apixaban is a substrate of both CYP3A4 and P-gp/BCRP transporters, according to the European Respiratory Review guidelines 1, 2
Cefpodoxime has not been identified as having clinically significant interactions with apixaban, unlike many small-molecule inhibitors used in cancer treatment 3, 4

Apixaban requires dose adjustment or contraindication only when combined with medications that are moderate to strong inhibitors of both CYP3A4 and P-gp/BCRP pathways, as recommended by the European Respiratory Review guidelines 1, 5
Cefpodoxime does not appear in any guidelines as a medication requiring special consideration when used with DOACs, unlike many cancer therapeutics 6, 7

The European Respiratory Review guidelines suggest that when prescribing antibiotics with DOACs, the primary concerns are medications that are known P-gp inhibitors, which cefpodoxime is not 8, 6
Cephalosporins, including cefpodoxime, are not listed among medications that significantly interact with apixaban in a way that would require dose adjustment or avoidance, according to the Anaesthesia guidelines 9, 10

Standard monitoring for patients on apixaban should continue regardless of cefpodoxime administration, as recommended by the European Respiratory Review guidelines 5
Patients on anticoagulation therapy should be observed for any unusual bleeding or bruising, but no special additional monitoring is required specifically due to the addition of cefpodoxime, according to the European Respiratory Review and Anaesthesia guidelines 4, 9

The European Respiratory Review guidelines note that this assessment applies specifically to cefpodoxime and apixaban; other antibiotics may have significant interactions with apixaban 1, 3
Individual patient factors such as age, renal function, and concomitant medications should still be considered when prescribing any medication to patients on anticoagulation, as recommended by the Anaesthesia guidelines 9
A comprehensive medication review is warranted if the patient is taking other medications that affect P-gp or CYP3A4 pathways, according to the European Respiratory Review guidelines 5, 6